Synapse - Works

Results (13087)

Subcutaneous epcoritamab with rituximab + lenalidomide (R(2)) in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): Update from phase 1/2 trial

Meeting Abstract

Falchi, L.; Leppä, S.; Wahlin, B. E.; Nijland, M.; Christensen, J. H.; De Vos, S.; Holte, H.; Linton, K. M.; Abbas, A.; Wang, L.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1/2 data update

Meeting Abstract

Falchi, L.; Offner, F.; Belada, D.; Brody, J.; Linton, K. M.; Karimi, Y.; Cordoba, R.; Snauwaert, S.; Abbas, A.; Wang, L.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Outcomes of single-agent PD-(L)-1 versus combination with chemotherapy in patients with PD-L1-high (≥ 50%) lung cancer

Meeting Abstract

Elkrief, A.; Machado Alessi, J. V.; Ricciuti, B.; Rizvi, H.; Preeshagul, I. R.; Egger, J. V.; Chaft, J. E.; Rudin, C. M.; Riely, G. J.; Kris, M. G.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convectionenhanced delivery for adult patients with recurrent malignant glioma (MG)

Meeting Abstract

Desjardins, A.; Chandramohan, V.; Landi, D. B.; Johnson, M. O.; Khasraw, M.; Peters, K. B.; Low, J.; Herndon, J. E.; Threatt, S.; Bullock, C. A.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Clinical characteristics and treatment outcomes in patients with histiocytic neoplasms harboring class 3 MAP2K1 mutations, including treatment with the ERK inhibitor ulixertinib

Meeting Abstract

Diamond, E. L.; Yabe, M.; Petrova-Drus, K.; Rosenblum, M.; Rotemberg, V.; Lacouture, M. E.; Rampal, R.; Francis, J.; Knoerzer, D.; Kreider, B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Overall survival by IDH2 mutant allele (R140 or R172) in patients with late-stage mutant-IDH2 relapsed or refractory acute myeloid leukemia treated with enasidenib or conventional care regimens in the phase 3 IDHENTIFY trial

Meeting Abstract

De Botton, S.; Risueño, A.; Schuh, A. C.; Lowenberg, B.; Kim, H. J.; Vyas, P.; Wei, A. H.; Stein, E. M.; Dohner, H.; Fathi, A. T.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Identification of response stratification factors from pooled efficacy analyses of afamitresgene autoleucel ("Afami-cel" [Formerly ADP-A2M4]) in metastatic synovial sarcoma and myxoid/round cell liposarcoma phase 1 and phase 2 trials

Meeting Abstract

D'Angelo, S. P.; Attia, S.; Blay, J. Y.; Strauss, S. J.; Morales, C. M. V.; Razak, A. R. A.; Van Winkle, E.; Annareddy, T.; Sattigari, C.; Diamantopoulos, E.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Bosutinib (BOS) in newly diagnosed chronic myeloid leukemia (CML): Gastrointestinal (GI), liver, effusion, and renal safety characterization in the BFORE trial

Meeting Abstract

Cortes, J. E.; Milojkovic, D.; Gambacorti-Passerini, C.; García-Gutierrez, V.; Mauro, M. J.; Leip, E.; Purcell, S.; Viqueira, A.; Brümmendorf, T. H.
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Primary efficacy and safety of letetresgene autoleucel (lete-cel; GSK3377794) pilot study in patients with advanced and metastatic myxoid/round cell liposarcoma (MRCLS)

Meeting Abstract

D'Angelo, S. P.; Druta, M.; Van Tine, B. A.; Liebner, D. A.; Schuetze, S.; Nathenson, M.; Holmes, A. P.; D'Souza, J.; Kapoor, G. S.; Zajic, S.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results

Meeting Abstract

Cowzer, D.; Wu, A. J. C.; Sihag, S.; Walch, H. S.; Park, B. J.; Jones, D. R.; Gu, P.; Maron, S. B.; Sugarman, R.; Chalasani, S. B.; more...
Journal of Clinical Oncology (2022)

Fulltext@MSK | Save